Patent ID: 11859000
Assignee: VACCINEX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 1:
2. The antibody, or antigen-binding portion thereof, of claim 1, which is capable of:
(a) enhancing an immune response to a tumor;
(b) reducing, depleting, or killing tumor infiltrating regulatory T (“Treg”) cells;
(c) inducing internalization of CCR8 in tumor infiltrating regulatory T (“Treg”) cells;
(d) activating NK cells,
(e) inducing NK cell mediated killing of tumor infiltrating regulatory T (“Treg”) cells;
(f) binding to cynomolgus monkey (“cyno”) CCR8;
(g) binding to human CCR8 with KD of 10 nM or less as measured by a binding assay utilizing surface plasmon resonance (SPR) analysis;
(h) inducing antibody-dependent cellular cytotoxicity (ADCC) in a subject following administration of the anti-CCR8 antibody;
(i) inducing upregulation of 4-1BB, ICAM-1, or both 4-1BB and ICAM-1 on the surface of NK cells;
(j) inducing down-regulation of CD16 on the surface of NK cells in the subject; or
(k) any combination thereof.